MDMA enhances emotional empathy and prosocial behavior

Hysek, Cédric M., Schmid, Yasmin, Simmler, Linda D., Domes, Gregor, Heinrichs, Markus, Eisenegger, Christoph, Preller, Katrin H., Quednow, Boris B. +1 more·2014·Social Cognitive and Affective Neuroscience
DOI 10.1093/scan/nst161

Cited by (355)

Items 201–300 of 355

  1. Does MDMA have treatment potential in sexual dysfunction? A systematic review of outcomes across the female and male sexual response cycles
    Ava Wexler, Alexandra Dubinskaya, Julie A. Suyama, Barry R. Komisaruk, Jennifer Tash Anger, KARYN SCHLUNT EILBER · 2023 · Sexual Medicine Reviews
  2. Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial
    Chiranth Bhagavan, Paul Glue, Will Evans, Lisa Reynolds, Thivya Turner, Chris King, Bruce R. Russell, Eva Morunga, Jessica Lee Mills, Geoff Layton et al. · 2024 · Trials
  3. Lack of evidence for positive reinforcing and prosocial effects of MDMA in pair-housed male and female rats
    Mark A. Smith, Karl T. Schmidt, Jessica L. Sharp, Tallia Pearson, Anna L. Davis, Abigail N. Gibson, Kenzie M. Potter · 2021 · European Journal of Pharmacology
  4. A Systematic Review of the MDMA Model to Address Social Impairment in Autism
    Devahuti Rai Chaliha, John C.L. Mamo, Matthew A. Albrecht, Virginie Lam, Ryusuke Takechi, Mauro Vaccarezza · 2021 · Current Neuropharmacology
  5. Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
    Tigran Makunts, Diane Dahill, Lisa Jerome, Alberdina de Boer, Ruben A Abagyan · 2023 · Frontiers in Psychiatry
  6. Development and initial validation of an MDMA/Ecstasy motives assessment
    James E. Sottile, Kathryn S. Macia, Robert E. Wickham, Nancy A. Haug · 2022 · Addictive Behaviors
  7. Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis)
    Sébastien Ballesta, Gilles Reymond, Matthieu Pozzobon, Jean‐René Duhamel · 2016 · PLoS ONE
  8. Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach
    Albert, Alexa E., Back, Anthony L. · 2025 · Frontiers in Psychiatry
  9. Naturalistic psychedelic experiences and gender-based self-acceptance in transgender and gender-expansive people
    Skylar J. Gaughan, Angie R. Wootton, Daphne Krantz, Alan K. Davis, Jennifer Elyse James, Rocco Rinaldi-Rose, Rafael Lancelotta, Jae M. Sevelius · 2025 · International Journal of Transgender Health
  10. Acute psychotropic, autonomic, and endocrine effects of 5,6‐methylenedioxy‐2‐aminoindane (MDAI) compared with 3,4‐methylenedioxymethamphetamine (MDMA) in human volunteers: A self‐administration study
    Verena Angerer, Yasmin Schmid, Florian Franz, Heike Gnann, Jan Manuel Speer, Anke Gnann, Stephan Helmecke, Armin Buchwald, Simon D. Brandt, Torsten Passie et al. · 2023 · Drug Testing and Analysis
  11. Putting the MD back into MDMA
    David Nutt, Harriet de Wit · 2021 · Nature Medicine
  12. An age-period-cohort analysis of trends in psychedelic and ecstasy use in the Australian population
    Gary Chan, Tianze Sun, Carmen C. W. Lim, Wing See Yuen, Daniel Stjepanović, Brienna N. Rutherford, Wayne Hall, Benjamin Johnson, Janni Leung · 2021 · Addictive Behaviors
  13. MDMA for the treatment of misophonia, a proposal
    Jadon Webb, Shannon Keane · 2022 · Frontiers in Psychiatry
  14. Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
    Katie Anderson, Patrick Elf, Amy Isham · 2024 · International Journal of Drug Policy
  15. Regular MDMA use is associated with decreased risk of drug injection among street-involved youth who use illicit drugs
    Andrew Gaddis, Stephanie Lake, Kenneth W. Tupper, Ekaterina Nosova, Katrina Blommaert, Evan Wood, Kora DeBeck · 2018 · Drug and Alcohol Dependence
  16. Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4‐fluoroamphetamine intoxication
    Patrick C. Dolder, Elizabeth B. de Sousa Fernandes Perna, Natasha Leigh Mason, Nadia R. P. W. Hutten, Stefan W. Toennes, Eef Lien Theunissen, Johannes Gerardus Ramaekers, Kim P. C. Kuypers · 2018 · Human Psychopharmacology Clinical and Experimental
  17. 3,4-Methylenedioxymethamphetamine (Mdma; Ecstasy) Use and Transitions to Injection Drug Use among Street-Involved Youth
    Stephanie Lake, Andrew Gaddis, Kenneth W. Tupper, Ekaterina Nosova, Kora DeBeck · 2018 · Substance Abuse
  18. Bringing MDMA-assisted therapy for PTSD to traditional healthcare systems: tending to set and setting
    Dimitri Perivoliotis, Kayla C. Knopp, Shannon Remick, Allie Kaigle, Christopher S. Stauffer, Chandra E. Khalifian, Tamara R. Wachsman, Bettye E. Chargin, Andrew W. Bismark, Al Alam et al. · 2025 · Frontiers in Psychiatry
  19. Effects of 3,4-methylenedioxymethamphetamine on the gut microbiota and metabolites in the small intestine, cecum, and colon of male rats
    Dan Xu, Akifumi Eguchi, Rumi Murayama, Guilin Liu, Mingming Zhao, Tingting Zhu, Yi Cai, Yong Gang Yue, Xiayun Wan, Yūkō Fujita et al. · 2024 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  20. Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain
    Adam W. Levin · 2024 · Journal of Psychopharmacology
  21. Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants
    Isabelle Straumann, Patrick Vizeli, Isidora Avedisian, Livio Erne, Diana Noorshams, Ina Vukalović, Anne Eckert, Dino Luethi, Deborah Rudin, Matthias E. Liechti · 2025 · Neuropsychopharmacology
  22. Neuroenhancement: State of the Art and Future Perspectives.
    Donatella Marazziti, Maria Teresa Avella, Tea Ivaldi, Stefania Palermo, Lucia Massa, Alessandra Della Vecchia, Lucia Basile, Federico Mucci · 2021 · PubMed Central
  23. Factors associated with neurofeedback and mindfulness-based combination therapy for patients with substance use disorder: A multicenter study
    Chih-Hsiang Chiu, Frank Huang‐Chih Chou, Hui‐Ching Wu, Chih‐Hung Ko, Meng-Chang Tsai, Jui-Kang Tsai, Chih‐Yao Hsu, Kuan‐Shang Chung, Yu-Shi Lu, Dian‐Jeng Li · 2024 · The European Journal of Psychiatry
  24. Psychedelic-Assisted Therapy for Social Adaptability in Autistic Adults
    Alicia L. Danforth · 2021 · Current topics in behavioral neurosciences
  25. Combinatorial approaches for treating neuropsychiatric social impairment
    Wei Don, Sherab Tsheringla, James C. McPartland, Stephen A. Allsop · 2022 · Philosophical Transactions of the Royal Society B Biological Sciences
  26. Phonological Markers of Oxytocin and MDMA Ingestion
    Carla Agurto, Raquel Norel, Rachel Ostrand, Gillinder Bedi, Harriet de Wit, Matthew J. Baggott, Matthew G. Kirkpatrick, Margaret C. Wardle, Guillermo Cecchi · 2017 · Interspeech (USB)
  27. Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders
    Clayton Olash, Derrick Matthew Buchanan, Randi E. Brown, Afik Faerman, Kirsten N. Cherian, George Lin, David Spiegel, James J. Gross, Nolan Williams · 2026 · npj Mental Health Research
  28. Women and MDMA: particularities of gender and sex
    Fábio Carezzato, Ilana Falcão de Arruda, Caio Petrus Monteiro Figueiredo, João Maurício Castaldelli-Maia · 2023 · International Review of Psychiatry
  29. From antidepressants and psychotherapy to oxytocin, vagus nerve stimulation, ketamine and psychedelics: how established and novel treatments can improve social functioning in major depression
    Aleksandra Kupferberg, Gregor Hasler · 2024 · Frontiers in Psychiatry
  30. Treatment of neuropathic pain with repeated low-dose MDMA: a case report
    Peter Gasser, Matthias E. Liechti, Friederike Holze · 2025 · Frontiers in Psychiatry
  31. History, pharmacology and therapeutic mechanisms of 3,4‐methylenedioxymethamphetamine (MDMA)
    Austen B. Casey, Boris Dov Heifets · 2025 · British Journal of Pharmacology
  32. Mystical Love: The Universal Solvent
    Charles D. Laughlin, Melanie Takahashi · 2020 · Anthropology of Consciousness
  33. Understanding the Effects of Lysergic Acid Diethylamide and the Importance of Its Prevention
    Burak Okumuş, A. Metin, I. Kariper · 2023 · Health Sciences Review
  34. To Produce or Not to Produce? Contrasting the Effect of Substance Abuse in Social Decision- Making Situations
    Laurent Ávila-Chauvet, Diana Mejía Cruz, Óscar García‐Leal, Bruno Kluwe‐Schiavon · 2022 · Heliyon
  35. Psychedelics for military and Veteran communities? Research, practice, and policy considerations
    Ron Shore · 2023 · Journal of Military Veteran and Family Health
  36. Subdiaphragmatic vagotomy reduces hypothalamic oxytocin expression and blood levels after oral MDMA administration in male rats
    Yong Gang Yue, Xiayun Wan, Guilin Liu, Tingting Zhu, Dan Xu, Mingming Zhao, Yi Cai, Rumi Murayama, Hirofumi Hashimoto, Naohiko Anzai et al. · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  37. Utilizing in Vivo and Imaginal Exposure in the Context of MDMA-Assisted Therapy for Social Anxiety Disorder: A Case Report
    Jason B. Luoma, Mary K. Lear, Kyong Yi, Brian C. Pilecki · 2025 · Cognitive and Behavioral Practice
  38. Pharmacies as potential providers of harm reduction services: A preliminary online survey
    E. James, T. Robertshaw, A. Westwell, A. Smith · 2018 · Drug Science Policy and Law
  39. Consommation d’ecstasy surdosé : à propos d’un cas mortel
    Pauline Thiebot, Marie Allard, Arezki Khaled Boukerma, Brigitte Delhotal, Pascal Houzé, Bruno Mégarbane, Laurence Labat · 2020 · Annales de Toxicologie Analytique
  40. MDMA – hopes and fears associated with therapeutic use in mental disorders
    Kamil Kozera, Lena Cichoń, Krzysztof Maria Wilczyński, Małgorzata Honorata Janas-Kozik · 2020 · Pharmacotherapy in Psychiatry and Neurology
  41. Methylone produces antidepressant-relevant actions and prosocial effects
    Zhenlong Li, Hsien‐Yu Peng, Chau‐Shoun Lee, Tzer‐Bin Lin, Ming‐Chun Hsieh, Cheng‐Yuan Lai, Han-Fang Wu, Lih‐Chyang Chen, Mei-Ci Chen, Dylan Chou · 2023 · Neuropharmacology
  42. Esketamine-induced post-traumatic stress disorder flashbacks during treatment-resistant depression indication: is it just a side effect?
    Maud Rothärmel, Lila Mékaoui, François Kazour, Morgane Herrero, Eva-Maria Beetz-Lobono, Aistė Lengvenytė, Jérôme Holtzmann, Philippe Raynaud, Macarena Cuenca, Samuel Bulteau et al. · 2024 · medRxiv
  43. Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA) in healthy volunteers: implications for therapeutic use
    Johannes Gerardus Ramaekers, Kim P. C. Kuypers, Franz X. Vollenweider · 2026 · Molecular Psychiatry
  44. Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress
    Noah D. Gold, Samantha K. Podrebarac, Lindsay A. White, Christina Marini, Naomi M. Simon, Mary Sherman Mittelman, Stephen Ross, Michael P. Bogenschutz, Petros D. Petridis · 2023 · Psychedelic Medicine
  45. The 3,4‐methylenedioxymethamphetamine enhances early visual processing for salient socio‐emotional stimuli
    Connor J. Haggarty, Anya K. Bershad, Mahesh K. Kumar, Royce Lee, Harriet de Wit · 2024 · European Journal of Neuroscience
  46. Including Sexually and Gender Diverse Populations in 3,4-Methylenedioxymethamphetamine–Assisted Psychotherapy Trial Research
    Ziad Saade, Brady D. Hanshaw, Alex Sogomon Keuroghlian · 2024 · LGBT Health
  47. Social Homeostasis and Psychoactive Drugs: What Can We Learn From Opioid and Amphetamine Drug Challenge Studies in Humans?
    Anya K. Bershad, Harriet de Wit · 2024 · Biological Psychiatry
  48. Anxiety-related Symptoms following the Sporadic Use of Ecstasy – A Case Study
    Tomislav Majić, Lasse Brandt, Christiane Montag · 2021 · Journal of Psychoactive Drugs
  49. Psychedelics for treating psychiatric disorders: Are they safe?
    Madonna Thakur · 2022 · Current Psychiatry
  50. Neurotransmitter modulation of human facial emotion recognition
    Myrto Vlazaki, Catherine J. Harmer, Philip J. Cowen, Erdem Pulcu · 2025 · Journal of Psychopharmacology
  51. Moral Enhancement by Technological Means: Possible, Permissible, a Duty?
    Toni Pustovrh, Monika McCollister Pirc · 2016 · Interdisciplinary Description of Complex Systems
  52. Addicted to Self-esteem: Understanding the neurochemistry of narcissism by using cocaine as a pharmacological model
    Alina Kastner-Bosek, Irena Dajic, Nace Mikuš, Ana Weidenauer, Matthäus Willeit · 2021 · Journal of Experimental Psychopathology
  53. Moral Enhancement – And the Opposite: Making People More or Less Moral
    Veljko Dubljević, Robert Ranisch · 2018 · Encyclopedia of Life Sciences
  54. Self-experience in MDMA assisted therapy of PTSD
    Bessel A. van der Kolk, Julie B. Wang, Rachel Yehuda, Leah Bedrosian, Allison R. Coker, Charlotte Harrison, Michael C. Mithoefer, Berra Yazar‐Klosinski, Amy Emerson, Rick Doblin · 2023 · medRxiv
  55. Psychedelics and cognitive function: A systematic review
    Caíque Gois Cardoso, Milena de Barros Viana · 2023 · Research Society and Development
  56. Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review
    Viktoriia Kurkova, Olga Winkler, Andrew James Greenshaw, Rakesh Jetly, Jennifer Swainson, Kalee Lodewyk, Parisa Saghafi, Liz Dennett, Lisa Burback · 2025 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  57. The Role of Psychedelics in Contemporary Psychological and Interdisciplinary Inquiry
    Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu, Joanne Marie Lusher · 2025 · Journal of Personalized Medicine
  58. State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
    Leslie A. Morland, Barbara O. Rothbaum, Lauren M. Sippel, Jessica L. Maples‐Keller, Paula P. Schnurr · 2026 · Journal of Traumatic Stress
  59. LSD acutely impairs fear recognition and enhances emotional empathy and sociality
    Patrick C. Dolder, Yasmin Schmid, Felix Müller, Stefan Borgwardt, Matthias E. Liechti · 2016 · European Neuropsychopharmacology
  60. Identification of a new M-ALPHA analog and MDMA in an illegal health product
    Ji Hyun Lee, Ok Rim Park, Suresh Mandava, Jemin Kim, Jaun Koo, Jongkook Lee, Hoil Kang · 2020 · Forensic Science International
  61. Pharmacological profiling of novel psychoactive substances
    Matthias E. Liechti, Linda D. Simmler, Harald H. Sitte, Dino Luethi · 2021 · Elsevier eBooks
  62. Intersectional Identities, Stigma and MDMA/Ecstasy Use
    Karenza Moore · 2022 · Springer eBooks
  63. Examining associations between MDMA/ecstasy and classic psychedelic use and impairments in social functioning in a U.S. adult sample
    Grant M. Jones, Joshua Lipson, Erica Wang · 2023 · Scientific Reports
  64. Propiedades psicométricas de la escala de prosocialidad de Caprara et al. (2005) en Colombia
    Virginia Barrero Toncel, Esteban Ocampo Flórez, Diana Cristina Barreto Sánchez, Ubaldo Enrique Rodríguez de Ávila · 2023 · psicogente
  65. 3,4-Methylenedioxymethamphetamine (MDMA) impairs cognitive function during withdrawal via activation of the arachidonic acid cascade in the hippocampus
    Yoko Nawata, Tsuyoshi Nishioku, Tsuneyuki Yamamoto, Taku Yamaguchi · 2024 · Drug and Alcohol Dependence
  66. Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition
    Alberto Sainz-Cort, Marta Martín-Islas, Daniel F. Jiménez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz Marrón, Luís Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens et al. · 2024 · International Clinical Psychopharmacology
  67. MDMA for treatment of PTSD and neurorehabilitation in military populations
    Walter Dunn, Anya K. Bershad, David E. Krantz, Eric H. G. J. M. Vermetten · 2024 · Neurorehabilitation
  68. Transdiagnostic use of 3,4-methylenedioxymethamphetamine-assisted therapy to treat obsessive–compulsive disorder
    Ziad Saade, Alex Sogomon Keuroghlian · 2025 · The British Journal of Psychiatry
  69. Societal Trends and Opportunities in the Aftermath of the Nova Psychedelic Trance Rave, Through Lilla and Benjamin
    Demian Halperin, Tal Bar On, Nir Tadmor, Alma Maria Simon, Aaron D. Cherniak, Guy Simon · 2025 · Future Humanities
  70. Is there a place for psychedelics in sports practice?
    Marina A. M. Portes, Isabel Werle, Leandro Jose Bertoglio · 2025 · Acta Neuropsychiatrica
  71. Can ketamine and other glutamate receptor modulators be considered entactogens?
    Hiroe Hu, Alaina N Tillman, Miyu Fujita, Mayu Yoshikawa, Elizabeth D. Ballard, Yoojin Lee, Carlos A. Zarate · 2025 · Psychiatry Research
  72. The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial
    Cihan Atila, Sara-Jessica Camerin, Matthias E. Liechti, Mirjam Christ‐Crain · 2025 · Endocrine Connections
  73. Neurochemistry of Prosocial Decision Making
    Carolyn H. Declerck, Christophe Boone · 2016 · Elsevier eBooks
  74. Biochemical contributions to interpersonal emotion dynamics
    Baldwin M. Way, Alexis Keaveney · 2018 · Cambridge University Press eBooks
  75. Conflict monitoring and emotional processing in 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine users – A comparative neurophysiological study
    Antje Opitz, Josua Zimmermann, David M. Cole, Rebecca C. Coray, Anna Zachäi, Markus R. Baumgartner, Andrea Eva Steuer, Maximilian Pilhatsch, Boris B. Quednow, Christian Beste et al. · 2024 · NeuroImage Clinical
  76. 3,4-Methylenedioxymethamphetamine (MDMA) consumption in Aotearoa New Zealand: A quantitative survey exploration
    Jai Whelan, Geoff Noller, Ryan D. Ward · 2024 · Drug Science Policy and Law
  77. Clinical pharmacology
    Severin B. Vogt, Matthias E. Liechti · 2025 · International review of neurobiology
  78. The effect of MDMA administration on oxytocin concentration levels: systematic review and a multilevel meta-analysis in humans
    Anna Vaslavski, Anna Harwood-Gross, Salomon Israel, Leehe Peled‐Avron · 2025 · Neuroscience & Biobehavioral Reviews
  79. Distribution of Serotonergic Transporter Innervation in the Nucleus Accumbens and Ventral Pallidum Is Highly Conserved Among Primates
    Heather N. Smith, Danielle N. Jones, Emily L. Munger, Patrick R. Hof, Chet C. Sherwood, Mary Ann Raghanti · 2025 · The Journal of Comparative Neurology
  80. The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust
    Ramona L. Martinez, Nina Radošić, Hanna M. Molla, Harriet de Wit, Sonja Lyubomirsky · 2025 · Journal of Psychopharmacology
  81. A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans
    Leehe Peled‐Avron, Jacob S. Aday, Madeline Marie Pantoni, Holly Hamilton, Joshua D. Woolley · 2025 · Scientific Reports
  82. Microfluidic Platform for On-site Simultaneous Analysis of Ketamine and MDMA in Urine
    Seulgi Lee, J. Yun, Joonseok Seo, Suncheun Kim, Jeongmin Lee, Yohan Jeong, Dami Kim, Juhyung Kim, Sangki Lee, Hyungchul Kim et al. · 2026 · BioChip Journal
  83. Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review
    Jennifer E. Thomas, Anna Dellarole, Joshua Caballero · 2026 · American Journal of Health-System Pharmacy
  84. Posttraumatic stress disorder from early childhood to late adolescence: a resilience-oriented approach to prevention, diagnosis, and clinical management
    Hala Kerbage, Éric Bui, Alexis Revet, H. Denis, Diane Purper‐Ouakil, Julie Rolling · 2026 · Discover Mental Health
  85. Substances of Abuse and Hallucinogenic Activity: The Serotoninergic Pathway - Focus on Classical Hallucinogens and Entactogens
    Matteo Lazzaretti, Gian Mario Mandolini, Alfredo Carlo Altamura, Paolo Brambilla · 2018 · Springer eBooks
  86. Møter med det hellige: bruk av LSD,fleinsopp og andre psykedeliske stoffer
    Willy Pedersen · 2020 · Tidsskrift for samfunnsforskning
  87. The Impact of Awe on Prosocial Behavior in the Post-Pandemic Era
    李瑶 徐 · 2023 · Advances in Psychology
  88. What Do Young Adults Expect from the Recreational Use of Ecstasy (3,4-Methylenedioxymethamphetamine/Molly)? A Latent Class Analysis of a Convenience Sample of Dutch Young Adults
    Martha Charlotta de Jonge, Andrea Johanna Bukman, Tom ter Bogt, Simone Arianne Onrust, Marloes Kleinjan · 2023 · European Addiction Research
  89. Linking Substance Use and Schizophrenia
    Emre Mutlu, Hayri Can Özden, Aygün Ertuğrul · 2024 · Springer eBooks
  90. Alcohol’s acute effects on emotion recognition and empathy in heavy-drinking young adults
    Lakshmi Kumar, Kasey G. Creswell, Kirk Warren Brown, Greta Lyons, Brooke C. Feeney · 2025 · Scientific Reports
  91. Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects
    Natalie Ertl, Imran Ashraf, Lisa Azizi, Leor Roseman, David Erritzøe, David Nutt, Robin Lester Carhart-Harris, Matthew B. Wall · 2025 · Neuropsychopharmacology
  92. Effects of Amphetamine-Type Stimulants on the Metabolome
    Andrea Eva Steuer · 2022 · Springer eBooks
  93. Ayahuasca and personality. A systematic review and meta-analysis of cross-sectional studies with long-term participants ( Ayahuasca y personalidad. Revisión sistemática y metaanálisis de estudios transversales con participantes de larga trayectoria )
    Ismael Apud · 2023 · Studies in Psychology Estudios de Psicología
  94. Seeking Happiness: Understanding the Mechanisms of Mixing Music and Drugs
    Kris Lam, Nafisa M. Jadavji · 2018
  95. Depression: Factors Contributing to Risk and Therapeutic Insights
    Ned H. Kalin · 2024 · American Journal of Psychiatry
  96. Using ‘hug drugs’ to understand affiliative behavior: the value of the social neurochemistry perspective.Commentary on:
    Ian D. Roberts, Baldwin M. Way · 2014 · Social Cognitive and Affective Neuroscience
  97. The Behavioral Effects of MDMA in Humans Under Controlled Laboratory Conditions
    Matthew G. Kirkpatrick, Casey R. Guillot, Carl L. Hart · 2016 · Elsevier eBooks
  98. Behavioural and Neurochemical Effects of Acute (±) 3,4 methylenedioxymethamphetamine (MDMA) in the Dopamine D1 Receptor Mutant Rat
    Hanna Squire · 2016
  99. Can 3,4,-methylenedioxymethamphetamine therapy be used to treat alcohol use disorder?
    Ben Sessa · 2017 · Journal of Psychedelic Studies
  100. Ethnography Of A Novel Remote Use Of An MDA Ceremony
    Greg Ferenstein · 2021 · SSRN Electronic Journal